ArticleOPEN ACCESS

Targets of opportunity for precision medicine

Blood
DOI: 10.1182/blood-2015-04-638270
0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Schinke et al have identified a higher expression of CXCR2 in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) stem cells than in normal hematopoietic stem cells (HSCs) and demonstrated preclinical therapeutic proof of principle

Cite

CITATION STYLE

APA

Saunthararajah, Y. (2015, May 14). Targets of opportunity for precision medicine. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2015-04-638270

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free